SPONSOR
Shanghai Pulmonary Hospital, Shanghai, China
Total Trials
6
Recruiting
6
Phases
Phase 2
Conditions studied: Lung CancerSmall-cell Lung CancerEGFR-mutant Non-small Cell Lung CancerPotentially ResectablePET-CTExtensive-stage Small Cell Lung Cancer (ES-SCLC)Thoracic NeoplasmsLung NeoplasmsLung DiseasesCystic Fibrosis, Pulmonary
NCT06749886 Phase 2
Recruiting
An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting
Lung Cancer
NCT04539977 Phase 2
Recruiting
PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer
Small-cell Lung Cancer
NCT07323056 Phase 2
Recruiting
Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer
EGFR-mutant Non-small Cell Lung Cancer
NCT07243873
Recruiting
Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study
Lung Cancer
NCT06758700 Phase 2
Recruiting
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
NCT05604495
Recruiting
Screening for Cystic Fibrosis and Cystic Fibrosis Related Disorders in Chinese Adults With Bronchiectasis
Cystic Fibrosis, Pulmonary